Stock of the Day

Johnson & Johnson (JNJ)

$273.39

-$1.81 (-0.7%)

Market Cap: $657.68B

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments.

The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson Bull Case

Here are some ways that investors could benefit from investing in Johnson & Johnson:

• Johnson & Johnson recently reported third-quarter adjusted earnings per share of $2.59, which exceeded the consensus estimate of $2.53, while revenue of $25.40 billion rose 5.9% year over year, demonstrating strong fundamental performance that supports the current stock price of $275.17.
• The company presented a record 26 abstracts at the 2026 Transcatheter Cardiovascular Therapeutics conference, adding to more than two decades of data on the safety, efficacy, and cost-effectiveness of its Impella heart pumps, which reinforces the competitive positioning of its MedTech portfolio.
• Johnson & Johnson is seeing rapid uptake of its oral plaque psoriasis therapy Icotyde in U.S. dermatology practices, with independent physician research indicating that prescriptions are building momentum and gaining share within the oral advanced therapy segment, potentially delaying the initiation of higher-cost biologic drugs.
• Broader strength among large pharmaceutical companies is helping sector sentiment, with peers like Merck and Eli Lilly posting strong results, which places Johnson & Johnson among several major healthcare names attracting significant investor interest and capital flows.
• The company maintains a stable dividend profile, having recently announced a quarterly dividend of $1.34 per share to be paid on December 8th, representing an annualized yield of approximately 1.9% that provides income stability for investors.

Johnson & Johnson Bear Case

Investors should be bearish about investing in Johnson & Johnson for these reasons:

• Pomerantz LLP is currently investigating claims on behalf of Johnson & Johnson investors, and while this does not establish wrongdoing, the renewed litigation attention may increase headline risk and investor uncertainty regarding the company's legal exposure.
• Johnson & Johnson trades at a premium valuation with a P/E ratio of 41.69, and analysts are questioning whether the recent gains adequately reflect future cash-flow growth, noting that potential earnings pressure in 2027 could limit further upside.
• Insiders have sold 64,515 shares of company stock worth approximately $17.27 million over the last 90 days, including recent sales by EVPs Jennifer Taubert and Elizabeth Forminard, which may signal a lack of confidence from company leadership at current price levels.
• The company's dividend payout ratio stands at 81.21%, which is relatively high and may limit the flexibility of management to reinvest in growth initiatives or absorb potential earnings shocks in the future.
• Short interest data shows that while the percentage of float shorted is low at approximately 0.70%, the absolute number of shares shorted remains significant at over 16.7 million, indicating that a portion of the market is still betting against the stock's performance.

Recent News

• Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors. (fool.com)
• Johnson & Johnson Just Took $7 Billion in Charges and Still Raised Its Outlook. Here's What That Tells Investors. (fool.com)
• No Tricks, Just Treats: 3 Dividend Stocks With Payouts You Can Trust (247wallst.com)
• 4 Dividend Kings With 50-Plus Years of Payout Increases for Retirement Income (247wallst.com)
• Does Johnson & Johnson (JNJ) Have A New Edge In Plaque Psoriasis? (finance.yahoo.com)
• Johnson & Johnson : Record 26 Abstracts at TCT 2026 Adds to More than 20 Years of Data Demonstrating the Safety, Efficacy and Cost Effectiveness of Impella Heart Pumps (marketscreener.com)
• Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher (247wallst.com)
• Merck Rises 5% as Earnings Beat Lifts Profit Outlook; Eli Lilly Climbs 7%, Johnson & Johnson Edges Higher (247wallst.com)
• VYM's Price May Be Soaring, but Its Dividend Isn't Keeping Up (247wallst.com)
• INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Johnson & Johnson - JNJ (prnewswire.com)